Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results
Antineoplastic Combined Chemotherapy Protocols
Prostatic Neoplasms, Castration-Resistant
rPFS was highly consistent and highly associated with OS, providing initial prospective evidence on further developing rPFS as an intermediate end point in mCRPC trials.
PubMed Central ID
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency